← Back to patent-cliff list
利塞膦酸钠
Tier C — Watch / tradeRisedronate Sodium Hydrate
宝洁公司
Originator
1998
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：FDPS
Brand：Actonel、Acrel、Benet、Atelvia、Optinate
Indications (approved)：佩吉特氏病、绝经期后骨质疏松、骨质疏松症、糖皮质激素诱导的骨质疏松
Regional status
US
批准上市
1998-03-27
EU
无进展
2001-10-01
China
批准上市
2004-03-18
Japan
批准上市
2002-01-17
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Risedronate Sodium Hydrate?
Approved indications include: 佩吉特氏病, 绝经期后骨质疏松, 骨质疏松症, 糖皮质激素诱导的骨质疏松.
When does the Risedronate Sodium Hydrate patent expire?
No public expiry year is available for Risedronate Sodium Hydrate yet; this page updates once verified.
How do I get a quote for Risedronate Sodium Hydrate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-25